Time-varying processes involved in smoking lapse in a randomized trial of smoking cessation therapies.
Time-varying processes involved in smoking lapse in a randomized trial of smoking cessation therapies.
复制标题
戒烟疗法随机试验中与吸烟衰退有关的时变过程。
DOI：
10.1093/ntr/ntt185
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Li,Runze
中科院分区：
文献类型：
--
作者：
Vasilenko,SaraA;Piper,MeganE;Lanza,StephanieT;Liu,Xiaoyu;Yang,Jingyun;Li,Runze
研究人员已经越来越多地开始收集关于吸烟的生态瞬时评估（EMA）数据，但新的统计方法是必要的，以充分释放这些数据的信息。在本文中，我们使用了一种新的技术，逻辑随时间变化的影响模型（逻辑TVEM），检查吸烟的几率在2周后戒烟attempt.MethodsData是从一个子样本的参与者从一个随机的，安慰剂对照试验的戒烟药物治疗谁实现了最初的禁欲（N = 1,106，58%的女性）。受试者在戒烟日后的2周内每天最多完成4次EMA评估。预测因素包括基线尼古丁依赖，渴望和负面影响的EMA测量，以及个体是否被分配到安慰剂，单药治疗或联合治疗条件。这些预测因素随时间变化的影响估计使用逻辑TVEM.ResultsCravings是一个显着的预测吸烟在整个2周postquit，而基线依赖的影响变得不显着的第二周，随着时间的推移，负面影响的影响增加。在单一疗法和联合治疗条件下的个人吸烟的几率下降，与安慰剂相比，在戒烟后的第一周，但这些差异在第二week. ConclusionsFindings无显着性表明，药物治疗更有效，与安慰剂相比，在戒烟尝试早，当基线尼古丁依赖对吸烟的影响更强，而随着时间的推移，渴望和负面影响的影响增加。未来的戒烟治疗可能会更成功，在戒烟尝试后的第二周提供额外的支持。
IntroductionResearchers have increasingly begun to gather ecological momentary assessment (EMA) data on smoking, but new statistical methods are necessary to fully unlock information from such data. In this paper, we use a new technique, the logistic time-varying effect model (logistic TVEM), to examine the odds of smoking in the 2 weeks after a quit attempt.MethodsData are from a subsample of participants from a randomized, placebo-controlled trial of smoking cessation pharmacotherapies who achieved initial abstinence (N= 1,106, 58% female). Participants completed up to 4 EMA assessments per day during the 2 weeks after their quit day. Predictors include baseline nicotine dependence, EMA measures of craving and negative affect, and whether an individual was assigned to a placebo, monotherapy, or combination therapy condition. Time-varying effects of these predictors were estimated using logistic TVEM.ResultsCravings were a significant predictor of smoking throughout the entire 2 weeks postquit, whereas the effect of baseline dependence became nonsignificant by the second week, and the effect of negative affect increased over time. Individuals in the monotherapy and combination therapy conditions had decreased odds of smoking compared with placebo in the first week postquit, but these differences were nonsignificant in the second week.ConclusionsFindings suggest that pharmacotherapies are more effective compared with placebo earlier in a quit attempt, when the effect of baseline nicotine dependence on smoking is stronger, whereas the effect of craving and negative affect increased over time. Future cessation therapies may be more successful by providing additional support in the second week after quit attempt.